In first meeting of FDA’s digital health advisory committee, generative AI is up for debate
Nov. 19, 2024
Robert Califf has made no secret of the Food and Drug Administration’s struggles to regulate generative AI. Large language models and their application to health care “provide a massive example of a technology with novel needs,” FDA commissioner Califf said in an address earlier this year to the Coalition for Health AI.
This week, the agency will turn toward that challenge, focusing the first-ever meeting of its Digital Health Advisory Committee on the question of whether and how generative AI should be regulated by the FDA. Over two full days, the committee will discuss questions about how to evaluate the performance of generative AI-enabled devices before and after they reach patients, and the risks that come with the technology.
advertisement
Why is it so hard to regulate generative AI products in medicine? To start, FDA officials wrote in an executive summary shared before the meeting, it’s hard to know when it qualifies as a device under the agency’s definitions.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$20
for 3 months, then $399/year
$20 for 3 months Get StartedThen $399/year
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe Log In Artificial intelligence, FDA, health tech, Policy, STAT+ Submit a correction requestReprints
Newsletter
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
